Inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), lead to abdominal pain and motility disturbances. In the gut endogenous lipids play a physiological role in gut homeostasis. Various enzymes, such as FAAH and FAAA are crucially involved in the modulation of physiological processes mediated by biolipids in the gastrointestinal (GI) tract such as palmitoylethanolamide.
In particular, for inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), whose symptoms are based on chronic irritation and inflammation in the gut as well as on motility disorders, molecules as PEA may replace in future conventional therapies for IBD and IBS.
The authors of the article:
‘Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract’
focus unnecessary on new chemical enzyme inhibitors for reaching higher endogenous levels of the protectove biollipids such as PEA. Simple oral ingestion of PEA as in PeaPure replenishes the system and leads to the same goal, without side effects often dose-limiting for enzyme inhibitors.
Source: Sałaga M, Sobczak M, Fichna J. Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract. Eur J Pharm Sci. 2013 Nov 22. pii: S0928-0987(13)00451-X. doi: 10.1016/j.ejps.2013.11.012. [Epub ahead of print]